Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

A 92-year-old man with a history of diffuse large B-cell lymphoma treated with chemoradiotherapy, and later with radiotherapy for an isolated cutaneous relapse with complete response, presented with a ...

Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and ...

(A) Schematic of the experimental design and analysis. Paracancerous and cancer tissues obtained from surgically resected DLBCLs were split and processed for scRNA-seq and spatial transcriptomics. (B) ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...

—A new study from Switzerland suggests that post-transplant lymphoproliferative disorders (PTLDs) may represent clonal expansions driven by exogenic immunosuppression, Epstein-Barr virus (EBV) ...

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...